Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury
The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are th...
Gespeichert in:
Veröffentlicht in: | The Journal of surgical research 1998-07, Vol.77 (2), p.91-98 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 98 |
---|---|
container_issue | 2 |
container_start_page | 91 |
container_title | The Journal of surgical research |
container_volume | 77 |
creator | Gupta, N. Jacobs, D.L. Miller, T.A. Smith, G.S. Dahms, T.E. |
description | The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components. |
doi_str_mv | 10.1006/jsre.1998.5344 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73906204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022480498953446</els_id><sourcerecordid>73906204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</originalsourceid><addsrcrecordid>eNp1kM2KFDEQgIMo6-zq1ZvQB_HWY36608lxWVZ3YMFFFMFLqElXa4buZEzSy_bNd_AN90nMMMPevFRRVV8VxUfIG0bXjFL5YZcirpnWat2KpnlGVozqtlayE8_JilLO60bR5iU5T2lHS607cUbOShStFivy_WbZhwcHj3_-fsHwsPxED9kFX92FjD47yJiqH8sUEvjq0mZ3Xzp9dTdCmqDe-H62pbz2fci_cHQwVhu_m-PyirwYYEz4-pQvyLeP11-vburbz582V5e3tRVS5ZprzlBSVG3bQqvsgNZCRyWTvRhYb5VSrNOtkI3UFpXm254rCsiYldsOmLgg74939zH8njFlM7lkcRzBY5iT6YSmktOmgOsjaGNIxdlg9tFNEBfDqDmYNAeT5mDSHEyWhbeny_N2wv4JP6kr83enOSQL4xDBW5eeMC4UZ0IWTB0xLBbuHUaTrENfrLmINps-uP998A-oA5Ed</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73906204</pqid></control><display><type>article</type><title>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Gupta, N. ; Jacobs, D.L. ; Miller, T.A. ; Smith, G.S. ; Dahms, T.E.</creator><creatorcontrib>Gupta, N. ; Jacobs, D.L. ; Miller, T.A. ; Smith, G.S. ; Dahms, T.E.</creatorcontrib><description>The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components.</description><identifier>ISSN: 0022-4804</identifier><identifier>EISSN: 1095-8673</identifier><identifier>DOI: 10.1006/jsre.1998.5344</identifier><identifier>PMID: 9733593</identifier><identifier>CODEN: JSGRA2</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Actins - metabolism ; Antibodies, Monoclonal - pharmacology ; Anticoagulants - pharmacology ; Biological and medical sciences ; Blood Proteins - pharmacology ; Blood Proteins - physiology ; Bucladesine - pharmacology ; Cardiovascular system ; Cells, Cultured ; Colforsin - pharmacology ; Complement System Proteins - physiology ; Cyclic AMP - metabolism ; Cytoskeleton - drug effects ; Cytoskeleton - metabolism ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - metabolism ; Hemostatics - pharmacology ; Heparin - pharmacology ; Humans ; Hypoxia - metabolism ; Medical sciences ; Oxygen - pharmacology ; Pharmacology. Drug treatments ; Receptors, Complement ; Solubility ; Thrombin - pharmacology ; Umbilical Veins - cytology ; Vascular wall ; Zymosan - pharmacology</subject><ispartof>The Journal of surgical research, 1998-07, Vol.77 (2), p.91-98</ispartof><rights>1998 Academic Press</rights><rights>1998 INIST-CNRS</rights><rights>Copyright 1998 Academic Press.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</citedby><cites>FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1006/jsre.1998.5344$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2382136$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9733593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, N.</creatorcontrib><creatorcontrib>Jacobs, D.L.</creatorcontrib><creatorcontrib>Miller, T.A.</creatorcontrib><creatorcontrib>Smith, G.S.</creatorcontrib><creatorcontrib>Dahms, T.E.</creatorcontrib><title>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</title><title>The Journal of surgical research</title><addtitle>J Surg Res</addtitle><description>The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components.</description><subject>Actins - metabolism</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Anticoagulants - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Blood Proteins - pharmacology</subject><subject>Blood Proteins - physiology</subject><subject>Bucladesine - pharmacology</subject><subject>Cardiovascular system</subject><subject>Cells, Cultured</subject><subject>Colforsin - pharmacology</subject><subject>Complement System Proteins - physiology</subject><subject>Cyclic AMP - metabolism</subject><subject>Cytoskeleton - drug effects</subject><subject>Cytoskeleton - metabolism</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Hemostatics - pharmacology</subject><subject>Heparin - pharmacology</subject><subject>Humans</subject><subject>Hypoxia - metabolism</subject><subject>Medical sciences</subject><subject>Oxygen - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Complement</subject><subject>Solubility</subject><subject>Thrombin - pharmacology</subject><subject>Umbilical Veins - cytology</subject><subject>Vascular wall</subject><subject>Zymosan - pharmacology</subject><issn>0022-4804</issn><issn>1095-8673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM2KFDEQgIMo6-zq1ZvQB_HWY36608lxWVZ3YMFFFMFLqElXa4buZEzSy_bNd_AN90nMMMPevFRRVV8VxUfIG0bXjFL5YZcirpnWat2KpnlGVozqtlayE8_JilLO60bR5iU5T2lHS607cUbOShStFivy_WbZhwcHj3_-fsHwsPxED9kFX92FjD47yJiqH8sUEvjq0mZ3Xzp9dTdCmqDe-H62pbz2fci_cHQwVhu_m-PyirwYYEz4-pQvyLeP11-vburbz582V5e3tRVS5ZprzlBSVG3bQqvsgNZCRyWTvRhYb5VSrNOtkI3UFpXm254rCsiYldsOmLgg74939zH8njFlM7lkcRzBY5iT6YSmktOmgOsjaGNIxdlg9tFNEBfDqDmYNAeT5mDSHEyWhbeny_N2wv4JP6kr83enOSQL4xDBW5eeMC4UZ0IWTB0xLBbuHUaTrENfrLmINps-uP998A-oA5Ed</recordid><startdate>19980701</startdate><enddate>19980701</enddate><creator>Gupta, N.</creator><creator>Jacobs, D.L.</creator><creator>Miller, T.A.</creator><creator>Smith, G.S.</creator><creator>Dahms, T.E.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980701</creationdate><title>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</title><author>Gupta, N. ; Jacobs, D.L. ; Miller, T.A. ; Smith, G.S. ; Dahms, T.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-2921e60e8555a58cfecca70616d3f1dc888179536469ce892bd280ae11c6b7a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Actins - metabolism</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Anticoagulants - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Blood Proteins - pharmacology</topic><topic>Blood Proteins - physiology</topic><topic>Bucladesine - pharmacology</topic><topic>Cardiovascular system</topic><topic>Cells, Cultured</topic><topic>Colforsin - pharmacology</topic><topic>Complement System Proteins - physiology</topic><topic>Cyclic AMP - metabolism</topic><topic>Cytoskeleton - drug effects</topic><topic>Cytoskeleton - metabolism</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Hemostatics - pharmacology</topic><topic>Heparin - pharmacology</topic><topic>Humans</topic><topic>Hypoxia - metabolism</topic><topic>Medical sciences</topic><topic>Oxygen - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Complement</topic><topic>Solubility</topic><topic>Thrombin - pharmacology</topic><topic>Umbilical Veins - cytology</topic><topic>Vascular wall</topic><topic>Zymosan - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, N.</creatorcontrib><creatorcontrib>Jacobs, D.L.</creatorcontrib><creatorcontrib>Miller, T.A.</creatorcontrib><creatorcontrib>Smith, G.S.</creatorcontrib><creatorcontrib>Dahms, T.E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of surgical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, N.</au><au>Jacobs, D.L.</au><au>Miller, T.A.</au><au>Smith, G.S.</au><au>Dahms, T.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury</atitle><jtitle>The Journal of surgical research</jtitle><addtitle>J Surg Res</addtitle><date>1998-07-01</date><risdate>1998</risdate><volume>77</volume><issue>2</issue><spage>91</spage><epage>98</epage><pages>91-98</pages><issn>0022-4804</issn><eissn>1095-8673</eissn><coden>JSGRA2</coden><abstract>The pathophysiology of ischemia–reperfusion injury and the role played by the interaction of plasma proteins, including complement, with reperfused endothelium remains incompletely understood. Venular endothelial changes due to hypoxia followed by reoxygenation (H-R) are vital because venules are the primary site of fluid accumulation and polymorphonuclear leukocyte deposition due to inflammation. This investigation focused on whether H-R potentiates the response to permeability inducing agents found in activated plasma. Activated complement was studied by using zymosan activated plasma (ZAP). Permeability changes were assessed by quantitating rate of clearance of albumin across the monolayers. H-R alone did not change permeability relative to the normoxic condition. ZAP at 2% in normoxic cells increased albumin clearance from 2 ± 0.2 to 9 ± 1.0 μL/h, which increased significantly to 13.5 ± 2.0 μL/h when given to hypoxia–reoxygenation challenged monolayers. The permeability response to ZAP was dose related and not present with heat inactivated ZAP. ZAP at 2% altered the structure of the cytoskeleton of the human umbilical vein endothelial cells (HUVEC). However, addition of monoclonal anti-complement antibodies or addition of soluble complement receptor-1 did not attenuate ZAP-induced HUVEC permeability. Addition of zymosan-activated serum did not alter the permeability and addition of heparin inhibited the ZAP-induced changes in permeability, suggesting that these changes were mediated via thrombin and not complement. The increase in monolayer permeability due to ZAP was prevented by increasing intracellular adenosine-3′,5′-cyclic monophosphate. These findings suggest that HUVEC monolayers challenged with H-R are more susceptible to increases in permeability induced by activated plasma components.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9733593</pmid><doi>10.1006/jsre.1998.5344</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-4804 |
ispartof | The Journal of surgical research, 1998-07, Vol.77 (2), p.91-98 |
issn | 0022-4804 1095-8673 |
language | eng |
recordid | cdi_proquest_miscellaneous_73906204 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Actins - metabolism Antibodies, Monoclonal - pharmacology Anticoagulants - pharmacology Biological and medical sciences Blood Proteins - pharmacology Blood Proteins - physiology Bucladesine - pharmacology Cardiovascular system Cells, Cultured Colforsin - pharmacology Complement System Proteins - physiology Cyclic AMP - metabolism Cytoskeleton - drug effects Cytoskeleton - metabolism Endothelium, Vascular - drug effects Endothelium, Vascular - metabolism Hemostatics - pharmacology Heparin - pharmacology Humans Hypoxia - metabolism Medical sciences Oxygen - pharmacology Pharmacology. Drug treatments Receptors, Complement Solubility Thrombin - pharmacology Umbilical Veins - cytology Vascular wall Zymosan - pharmacology |
title | Hypoxia–Reoxygenation Potentiates Zymosan Activated Plasma-Induced Endothelial Injury |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A40%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypoxia%E2%80%93Reoxygenation%20Potentiates%20Zymosan%20Activated%20Plasma-Induced%20Endothelial%20Injury&rft.jtitle=The%20Journal%20of%20surgical%20research&rft.au=Gupta,%20N.&rft.date=1998-07-01&rft.volume=77&rft.issue=2&rft.spage=91&rft.epage=98&rft.pages=91-98&rft.issn=0022-4804&rft.eissn=1095-8673&rft.coden=JSGRA2&rft_id=info:doi/10.1006/jsre.1998.5344&rft_dat=%3Cproquest_cross%3E73906204%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73906204&rft_id=info:pmid/9733593&rft_els_id=S0022480498953446&rfr_iscdi=true |